Economic Analysis of Rivaroxaban for the Treatment and Long-Term Prevention of Venous Thromboembolism in Portugal

Authors

  • Isabel Fonseca Santos Bayer Portugal, S.A. Carnaxide. Portugal.
  • Sónia Pereira Bayer Portugal, S.A. Carnaxide. Portugal.
  • Euan McLeod IMS Health. London. United Kingdom.
  • Anne-Laure Guillermin IMS Health. London. United Kingdom.
  • Ismini Chatzitheofilou IMS Health. London. United Kingdom.

DOI:

https://doi.org/10.20344/amp.5257

Abstract

Introduction: Venous thromboembolism is a burden on healthcare systems. The aim of this analysis was to project the long-term costs and outcomes for rivaroxaban compared to standard of care (enoxaparin/warfarin) in Portugal for the treatment and secondary prevention of venous thromboembolism.
Material and Methods: A Markov model was developed using event rates extracted from the EINSTEIN trials supplemented with literature-based estimates of longer-term outcomes. Core outcomes included per patient costs and quality-adjusted life years reported separately per treatment arm and incrementally, as well as cost per quality-adjusted life years gained. The deep vein thrombosis and pulmonary embolism indications were analysed separately. The analyses were conducted from the Portuguese societal perspective and over a 5-year time horizon. Costs and outcomes were discounted at a 5% annual rate. Several scenario analyses were undertaken to explore the impact on results of varying key modeling assumptions.
Results: Rivaroxaban treatment was associated with cost-savings for the treatment of deep vein thrombosis and was both cost-saving and more effective for the treatment of pulmonary embolism, compared with enoxaparin/warfarin.
Discussion: The results of the sensitivity and scenario analyses further supported that rivaroxaban is a cost-effective alternative to standard of care treatment. The use of an expert panel to derive some input values and the lack of Portuguese specific utilities were the main limitations.
Conclusion: Rivaroxaban represents an efficient alternative to using enoxaparin/warfarin in Portugal, as it’s associated with lower costs (for both indications) and greater quality adjusted life years (for the pulmonary embolism indication).


Keywords: Venous Thrombosis; Pulmonary Embolism; Rivaroxaban; Venous Thromboembolism.

Downloads

Download data is not yet available.

Author Biographies

Isabel Fonseca Santos, Bayer Portugal, S.A. Carnaxide. Portugal.

Sónia Pereira, Bayer Portugal, S.A. Carnaxide. Portugal.

Euan McLeod, IMS Health. London. United Kingdom.

Anne-Laure Guillermin, IMS Health. London. United Kingdom.

Ismini Chatzitheofilou, IMS Health. London. United Kingdom.

Downloads

Published

2014-10-30

How to Cite

1.
Santos IF, Pereira S, McLeod E, Guillermin A-L, Chatzitheofilou I. Economic Analysis of Rivaroxaban for the Treatment and Long-Term Prevention of Venous Thromboembolism in Portugal. Acta Med Port [Internet]. 2014 Oct. 30 [cited 2024 Mar. 29];27(5):615-24. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/5257